1.2 OMIM# of the disease 604772, 611938
1.3 Name of the analysed genes or DNA/chromosome segments RyR2, cardiac ryanodine receptor; CASQ2, cardiac calsequestrin.
OMIM# of the gene(s) 180902, 114251
Two genes are clearly associated with CPVT (RyR2 autosomal dominant and CASQ2 autosomal recessive). Triadin and calmodulin mutations have been shown in possible CPVT cases and in one family with stress-induced sudden death. In the clinical setting, the analysis of these two genes may be indicated (yield yet unknown) when RyR2 and CASQ2 screening is negative.
Mutational spectrum
Mutations are mainly missense. Exon 3 deletion is reported in two families with exercise-induced arrhythmias but also non-typical CPVT arrhythmias (sinoatrial node and atrioventricular node dysfunction, and atrial standstill) and dilated cardiomyopathy.
Analytical methods
Direct DNA sequencing.
Analytical validation
Sequencing of both strands. When a mutation is identified, one should validate the mutation in an independent experiment by direct sequencing using a freshly prepared DNA dilution.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence)
Prevalence is estimated in 1:10 000 but robust estimates are unavailable.
1.9 If applicable, prevalence in the ethnic group of investigated person No data available.
Diagnostic setting
Yes No
Prenatal testing is available when mutation in the family is known. 
TEST CHARACTERISTICS
Negative C D Positive predictive value: Negative predictive value: 
How is the cost effectiveness of alternative diagnostic methods to be judged?
When a disease-causing mutation is identified in the index patient, genetic testing can be offered to apparently healthy relatives within the family to determine whether they carry the same mutation and are at risk of developing the disease. If the relative carries the mutation, a therapy is always indicated even in asymptomatic subjects without signs of the disease, given the risk of sudden death as first manifestation of the disease. All mutation carriers should be treated lifelong with non-selective beta blockers (propranolol or nadolol). Flecainide can be added for non-responders. The achievement of a satisfactory therapeutic effect can be assessed with exercise-stress test in the majority of cases. Regular medical follow-up is required to reassess the effective control of cardiac arrhythmias. Specific advice to mutation carriers might include restriction of physical activity (arrhythmias are triggered by catecholamine release), avoidance of specific careers and reproductive counseling. If a relative does not carry the mutation then they can be reassured and cardiological follow-up discontinued (provided that severity of the phenotype in any family member does not suggest multiple genetic events).
Will disease management be influenced by the result of a genetic test?
No &
Yes 2

Therapy (please describe)
Beta blocker therapy should be given to silent mutation carriers, given the possibility of sudden death as first manifestation of the disease. Prognosis Restriction of physical activity and avoidance of acute stress/ emotions is mandatory to all mutation carriers.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe):
Avoidance of physical activity is indicated for all mutation carriers (both with and without phenotype).
If the test result is negative (please describe): Subjects with clinical diagnosis and no mutations on the known genes should be treated and managed as those with a mutation.
Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?
The same as with a positive genetic test.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked) Yes. All family members should undergo targeted-mutation(s) screening. All known genes should be entirely screened in the proband. 
Prenatal diagnosis
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
Even in the presence of clinically diagnosed and correctly treated CPVT in the proband, genetic testing is useful to identify at-risk family members.
